Skip to main content Skip to main navigation menu Skip to site footer

The relationship between hepcidin and anemia in controlled and uncontrolled Type-2 Diabetes Mellitus (T2DM) patients at Sanglah Hospital, Bali, Indonesia

  • Ni Ketut Puspa Sari ,
  • I Nyoman Wande ,
  • I Ketut Suega ,
  • I.A. Putri Wirawati ,
  • Ni Nyoman Mahartini ,
  • Sianny Herawati ,


Background: Anemia in patients with diabetes mellitus (DM) is often associated with anemia of chronic disease caused by inflammation or iron metabolism disorders. Hepcidin is known to function in initiating the internalization and degradation of ferroportin. It can inhibit the release of iron from cells where an increase in hepcidin levels will reduce iron absorption in the intestine, resulting in a decrease in serum iron levels. This study aims to determine the relationship between serum hepcidin levels and anemia in patients with Type-2 Diabetes Mellitus (T2DM).

Methods: This cross-sectional study was conducted on 77 consecutive T2DM patients who met the inclusion and exclusion criteria and received health services at Sanglah Hospital, Bali, Indonesia, during the study period. The variables assessed in this study included T2DM status (controlled and uncontrolled), anemia, hemoglobin, HbA1c, erythrocyte sedimentation rate, and hepcidin. Data were analyzed with SPSS version 20 for Mac.

Results: There was no significant difference in age, sex, disease duration, SGOT, SGPT, leukocytes, platelets, and ESR between controlled and uncontrolled T2DM groups (p>0.05). However, there was a significant difference in eGFR and hemoglobin levels between controlled and uncontrolled T2DM groups (p<0.05). Mann-Whitney U test found a significant difference in hepcidin levels between controlled and uncontrolled T2DM groups (MD=138.14; 95%CI=10.65-286.94; p=0.046). A weak significant negative correlation was found between hemoglobin and hepcidin levels by the Spearman correlation test (r=-0.259; p=0.043).

Conclusion: There was a significant difference between the mean hemoglobin and hepcidin levels in the controlled T2DM group compared to uncontrolled T2DM group patients. A weak statistically significant negative correlation was found between hepcidin levels and anemia in T2DM patients.



  1. Zheng Y, Ley SH, Hu FB. Global aetiology and epidemiology of type 2 diabetes mellitus and its complications. Nat Rev Endocrinol. 2018;14(2):88-98.
  2. Mulyani WRW, Sanjiwani MID, Sandra, Prabawa IPY, Lestari AAW, Wihandani DM, et al. Chaperone-Based Therapeutic Target Innovation: Heat Shock Protein 70 (HSP70) for Type 2 Diabetes Mellitus. Diabetes Metab Syndr Obes. 2020;13:559-568.
  3. Pickup JC, Chusney GD, Thomas SM, Burt D. Plasma interleukin-6, tumour necrosis factor alpha and blood cytokine production in type 2 diabetes. Life Sci. 2000;67(3):291-300.
  4. Barbieri J, Fontela PC, Winkelmann ER, Zimmermann CE, Sandri YP, Mallet EK, et al. Anemia in Patients with Type 2 Diabetes Mellitus. Anemia. 2015;2015:354737.
  5. Pasricha SR, McQuilten Z, Westerman M, Keller A, Nemeth E, Ganz T, et al. Serum hepcidin as a diagnostic test of iron deficiency in premenopausal female blood donors. Haematologica. 2011;96(8):1099-105.
  6. Suega K. Role of hepcidin in mechanism of anemia chronic disease patients. Bali Medical Journal. 2014;3(2):89-96.
  7. Fernández-Real JM, López-Bermejo A, Ricart W. Iron stores, blood donation, and insulin sensitivity and secretion. Clin Chem. 2005;51(7):1201-1205.
  8. Aso Y, Takebayashi K, Wakabayashi S, Momobayashi A, Sugawara N, Terasawa T, et al. Relation between serum high molecular weight adiponectin and serum ferritin or prohepcidin in patients with type 2 diabetes. Diabetes Res Clin Pract. 2010;90(3):250-255.
  9. Sam AH, Busbridge M, Amin A, Webber L, White D, Franks S, et al. Hepcidin levels in diabetes mellitus and polycystic ovary syndrome. Diabet Med. 2013;30(12):1495-1499.
  10. Aigner E, Felder TK, Oberkofler H, Hahne P, Auer S, Soyal S, et al. Glucose acts as a regulator of serum iron by increasing serum hepcidin concentrations. J Nutr Biochem. 2013;24(1):112-117.
  11. Jiang F, Sun ZZ, Tang YT, Xu C, Jiao XY. Hepcidin expression and iron parameters change in Type 2 diabetic patients. Diabetes Res Clin Pract. 2011;93(1):43-48.
  12. Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care. 2004;27(5):1047-1053.
  13. Handayani SA. Faktor-Faktor Risiko Diabetes Melitus Tipe-2 di Semarang dan Sekitarnya (Studi Kasus di RSUP Dr.Kariadi dan RSUD Kota Semarang) [Tesis]. Program Pasca Sarjana Universitas Diponegoro: Semarang. 2003.
  14. Silangit T, Anto EJ. Gambaran Kadar HbA1c pada Penderita Diabetes Mellitus di Klinik Diabetes Dharma Medan. Majalah Ilmiah METHODA. 2018;8(1):103-107.
  15. Scavini M, Stidley CA, Shah VO, Narva AS, Tentori F, Kessler DS, et al. Prevalence of diabetes is higher among female than male Zuni indians. Diabetes Care. 2003;26(1):55-60.
  16. Kautzky-Willer A, Harreiter J, Pacini G. Sex and Gender Differences in Risk, Pathophysiology and Complications of Type 2 Diabetes Mellitus. Endocr Rev. 2016;37(3):278-316.
  17. Abbate R, Mannucci E, Cioni G, Fatini C, Marcucci R. Diabetes and sex: from pathophysiology to personalized medicine. Intern Emerg Med. 2012;7 Suppl 3:S215-S219.
  18. Glassock RJ, Warnock DG, Delanaye P. The global burden of chronic kidney disease: estimates, variability and pitfalls. Nat Rev Nephrol. 2017;13(2):104-114. doi:10.1038/nrneph.2016.163
  19. Jin H, Zhou J, Wu C. Prevalence and health correlates of reduced kidney function among community-dwelling Chinese older adults: the China Health and Retirement Longitudinal Study. BMJ Open. 2020;10(12):e042396.
  20. Drawz P, Rahman M. Chronic kidney disease. Ann Intern Med. 2015;162(11):ITC1-ITC16.
  21. Cappellini MD, Motta I. Anemia in Clinical Practice-Definition and Classification: Does Hemoglobin Change With Aging?. Semin Hematol. 2015;52(4):261-269.
  22. Setianingsih E, Budiwiyono I, Hendrianingtyas M. Perbedaan petanda osteoporosis dan inflamasi pada pasien diabetes melitus tipe 2 terkontrol dan tidak terkontrol. Intisari Sains Medis. 2020;11(2):511-516.
  23. Aljohani AH, Alrubyyi MA, Alharbi AB, Alomair AM, Alomair AA, Aldossari NA, et al. The Relation Between Diabetes Type II and Anemia. The Egyptian Journal of Hospital Medicine. 2018;70(4):526-531.
  24. Shaheen ES. Prevalence of Anemia in Patients with Type 2 Diabetes. Journal of Medicine in Scientific Research. 2019;2(2):114-117.
  25. Al-Adhami IAA, Al-Shamahy HA, Al-Meeril AM. Plasma Ferritin and Hepcidin Levels in Patients With Type 2 Diabetes Mellitus. Universal Journal of Pharmaceutical Research. 2019;4(1):1-6.
  26. Guo X, Zhou D, An P, Wu Q, Wang H, Wu A, et al. Associations between serum hepcidin, ferritin and Hb concentrations and type 2 diabetes risks in a Han Chinese population. Br J Nutr. 2013;110(12):2180-5.
  27. Andrews M, Soto N, Arredondo-Olguín M. Association between ferritin and hepcidin levels and inflammatory status in patients with type 2 diabetes mellitus and obesity. Nutrition. 2015;31(1):51-57.
  28. Narang V, Grover S, Kang AK, Garg A, Sood N. Comparative Analysis of Erythrocyte Sedimentation Rate Measured by Automated and Manual Methods in Anaemic Patients. J Lab Physicians. 2020;12(4):239-243.
  29. Bikramjit P, Raveender N, Sudipta P. The Importance of HbA1c and Erythrocyte Sedimentation Rate as Prognostic Factor in Predicting the Outcome of Diabetic Foot Ulcer Disease. International Journal of Advances in Medicine. 2017:4(1):137-142.
  30. Park CH, Valore EV, Waring AJ, Ganz T. Hepcidin, a urinary antimicrobial peptide synthesized in the liver. J Biol Chem. 2001;276(11):7806-7810.
  31. Ganz T. Hepcidin, a key regulator of iron metabolism and mediator of anemia of inflammation. Blood. 2003;102(3):783-788.
  32. Nemeth E, Valore EV, Territo M, Schiller G, Lichtenstein A, Ganz T. Hepcidin, a putative mediator of anemia of inflammation, is a type II acute-phase protein. Blood. 2003;101(7):2461-2463.
  33. Ganz T. Hepcidin and its role in regulating systemic iron metabolism. Hematology Am Soc Hematol Educ Program. 2006;29-507.
  34. Albendary E, Al-Shehaa M. A comparative Study Between Serum Hepcidin Level, Iron Status and Iron Deficiency Anemia Among Recently Diagnosed Gestational Diabetes Mellitus in Qassim Area KSA. Tanta Medical Science Journal. 2011;6(3):107-117.
  35. Hong JH, Choi YK, Min BK, Park KS, Seong K, Lee IK, et al. Relationship between hepcidin and GDF15 in anemic patients with type 2 diabetes without overt renal impairment. Diabetes Res Clin Pract. 2015;109(1):64-70.
  36. Zaritsky J, Young B, Wang HJ, Westerman M, Olbina G, Nemeth E, et al. Hepcidin--a potential novel biomarker for iron status in chronic kidney disease. Clin J Am Soc Nephrol. 2009;4(6):1051-6.

How to Cite

Sari, N. K. P., Wande, I. N., Suega, I. K., Wirawati, I. P., Mahartini, N. N., & Herawati, S. (2021). The relationship between hepcidin and anemia in controlled and uncontrolled Type-2 Diabetes Mellitus (T2DM) patients at Sanglah Hospital, Bali, Indonesia. Indonesia Journal of Biomedical Science, 15(2), 140–144.




Search Panel